Overall, LS confers a lifetime risk of CRC up to 60%; however, this varies by genotype, with MSH6 and PMS2 PGV carriers having lower CRC risk compared to those carrying a MLH1, MSH2, or EPCAM PGVs [6]. This evidence concerns the gene MSH6 and colorectal carcinoma.